From your third link, the metastudy with the most power: "GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI 0.86-1.97), hyperthyroidism (RR 1.19, 95% CI 0.61-2.35), hypothyroidism (RR 1.22, 95% CI 0.80-1.87), thyroiditis (RR 1.83, 95% CI 0.51-6.57), thyroid mass (RR 1.17, 95% CI 0.43-3.20), and goiter (RR 1.17, 95% CI 0.74-1.86)."

The only significant finding was "an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60)."

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309474/

Scientific literacy is important. The contributions to that meta-study were predominantly looking at 1-2 year outcomes, with a few outliers, which gives means it draws little insight with regard to what might apply from long-term (or lifetime!) use.

The abstract of the paper itself concludes "However, due to the low incidence of these diseases, these findings need to be examined further." suggesting that the authors didn't even find their own work to be conclusive about the short/medium-term risks at the scale of widespread use, let alone the long-term risks that they weren't even analyzing.

> Scientific literacy is important

Straw man. Nobody claimed these studies prove GLP-1 agonists are totally safe. Just that they don't show "severe unknown incidents like thyroid and pancreatic cancer" [1].

> suggesting that the authors didn't even find their own work to be conclusive about the short/medium-term risks at the scale of widespread use, let alone the long-term risks that they weren't even analyzing

Sure. That's a straightforward reading of the paper. Again, nobody argued these aren't thesre. Just that present data don't sustain it as a serious problem.

[1] https://news.ycombinator.com/item?id=40565348

From your last study cited...

>However, no major safety concerns have arisen to date, although definitive conclusions for pancreatic cancer, thyroid cancer and DRP complications cannot be drawn at this point. When compared with the beneficial effects of these drugs on glucose metabolism, blood pressure, body weight and cardiovascular (and potentially even renal) endpoints, these agents have an overall beneficial risk/benefit-profile for treatment of patients with T2D.